| J. Pharm. Sci.
| [0039]
|
| McGraw-Hill Dictionary of Chemical Terms
| [0049]
|
| Stereochemistry of Organic Compounds
| [0049]
|
| J. Med. Chem.
| [0077]
|
| Cancer research
| [0077]
|
| Critical reviews in oncology/haematology
| [0077]
|
| Remington's Pharmaceutical Sciences
| [0082]
|
| Leukemia
| [0255]
|
| Biochemistry
| [0255]
|
| Nat. Genet.
| [0255]
|
| Blood
| [0255]
|
| Genetics
| [0255]
|
| Leukemia
| [0255]
|
| Cancer Cell
| [0255]
|
| Nat Med
| [0255]
|
| CA Cancer J Clin
| [0255]
|
| Nature
| [0255]
|
| Nature
| [0255]
|
| Nature
| [0255]
|
| J Neurosci
| [0255]
|
| Drugs
| [0255]
|
| Leukemia
| [0255]
|
| Hum Mol Genet
| [0255]
|
| Methods
| [0255]
|
| Blood
| [0255]
|
| Nat Rev Cancer
| [0255]
|
| Moz (MYST3, KAT6a) inhibitis senescence via the INK4A-ARF pathway
| [0255]
|
| MOZ regulates B cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development
| [0255]
|
| Leuk Res
| [0255]
|
| Development
| [0255]
|
| Genes Dev
| [0255]
|
| Cell Cycle
| [0255]
|
| Genes Chromosomes Cancer
| [0255]
|
| Mol Cell Biol
| [0255]
|